Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cochrane on Bisphosphonates for Breast Cancer

Cochrane; 2017 Oct 30; O'Carrigan, Wong, et al

Bisphosphonates reduce the risk of bone metastases in women with breast cancer and enable those who take them to live longer than those receiving placebo or no bisphosphonates, according to a Cochrane review of 44 studies involving >37,000 individuals.

In women with early breast cancer, bisphosphonates:

  • Probably lowered the risk of cancer spreading to the bone.
  • Improved survival, but the benefit in the whole group was small.
  • Improved survival and reduced the risk of cancer returning in postmenopausal women.

In women with metastatic breast cancer that spread to the bone:

  • Bisphosphonates reduced fractures and bone pain.
  • They did not appear to increase the length of time women survived.
  • Quality of life was slightly better for women who took bisphosphonates.
  • Denosumab reduced the risk of complications compared to bisphosphonates, but it did not produce a survival benefit.

In women with advanced breast cancer, bisphosphonates did not reduce the risk of cancer spreading to the bone or improve survival.

Citation:

O'Carrigan B, Wong M, Willson M, Stockler M, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Syst Rev. 2017, Issue 10. Art. No.: CD003474. doi:10.1002/14651858.CD003474.pub4.

This Week's Must Reads

Cochrane on Bisphosphonates for Breast Cancer, Cochrane; 2017 Oct 30; O'Carrigan, Wong, et al

Fiber Intake and Survival After CRC Diagnosis, JAMA Oncol; ePub 2017 Nov 2; Song, Wu, et al

Selecting Patients with Advanced NSCLC for Chemo, JAMA Oncol; ePub 2017 Nov 1; Shen, Chang, et al

Predicting CV Risk in Childhood Cancer Survivors, J Clin Oncol; ePub 2017 Nov 2; Chow, Chen, et al

CD8+ Tumor-Infiltrating Lymphocytes and Ovarian Ca, JAMA Oncol; ePub 2017 Oct 12; OTTA Consortium

Must Reads in Breast Cancer

Cochrane on Bisphosphonates for Breast Cancer, Cochrane; 2017 Oct 30; O'Carrigan, Wong, et al

ASCO Updates Guideline on Role of BMAs in BC, J Clin Oncol; ePub 2017 Oct 16; Van Poznak, et al

This Assay Altered Treatment in Patients with BC, JAMA Oncol; ePub 2017 Oct 26; Tsai, Lo, et al

Cardiac Function with These BC Meds Evaluated, J Clin Oncol; ePub 2017 Oct 26; Ganza, et al

Verzenio Approved for Certain Breast Cancers, FDA news release; 2017 Sep 28